Multifocal Retinopathy in Dachshunds With CLN2 Neuronal Ceroid Lipofuscinosis [PDF]
The CLN2 form of neuronal ceroid lipofuscinosis is an autosomal recessively inherited lysosomal storage disease that is characterized by progressive vision loss culminating in blindness, cognitive and motor decline, neurodegeneration, and premature death.
Martin L Katz +2 more
exaly +3 more sources
Rapid and reversible regulation of cell cycle progression in budding yeast using optogenetics [PDF]
Summary: The complexity of the eukaryotic cell cycle complicates experiment design and data interpretation, limiting our understanding of how cells coordinate cell cycle processes.
Andriana Koutsoumpa +3 more
doaj +2 more sources
Biofluid Proteomic Biomarker Discovery in a Large Animal Model of CLN2 Neuronal Ceroid Lipofuscinosis [PDF]
CLN2 disease is a fatal lysosomal storage disorder caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1), resulting in progressive neurodegeneration and non-neuronal pathology.
Brandie R. Morgan-Jack +8 more
doaj +2 more sources
Recreating pathophysiology of CLN2 disease and demonstrating reversion by TPP1 gene therapy in hiPSC-derived retinal organoids and retina-on-chip [PDF]
Summary: Mutations in the tripeptidyl peptidase 1 (TPP1) gene lead to neuronal ceroid lipofuscinosis type 2 (CLN2), characterized by lysosomal accumulation of lipofuscins predominantly in the brain and retina.
Serena Corti +24 more
doaj +2 more sources
Role of Swi4 in cell cycle regulation of CLN2 expression. [PDF]
Expression of the Saccharomyces cerevisiae CLN1 and CLN2 genes is cell cycle regulated, and the genes may be controlled by positive feedback. It has been proposed that positive feedback operates via Cln/Cdc28 activation of the Swi4/Swi6 transcription factor, leading to CLN1 and CLN2 transcription due to Swi4 binding to specific sites (SCBs) in the CLN1
Cross, F R +3 more
openaire +4 more sources
Molecular Basis of the Functional Distinction Between Cln1 and Cln2 Cyclins [PDF]
Cln1 and Cln2 are very similar but not identical cyclins. In this work, we tried to describe the molecular basis of the functional distinction between Cln1 and Cln2. We constructed chimeric cyclins containing different fragments of Cln1 and Cln2 and performed several functional analysis that make it possible to distinguish between Cln1 or Cln2.
Juan Carlos Igual, Inma Quilis
exaly +3 more sources
Chronic oral cannabidiol delays seizure onset and reduces seizure burden in a mouse model of CLN2 disease [PDF]
A growing body of literature describes the anti-inflammatory, neuroprotective, and anti-epileptic properties of the cannabis sativa constituent cannabidiol, suggesting that it might play a ...
Nicholas R. Rensing +11 more
core +2 more sources
Age at onset and gene variants predict lifespan and disease duration in childhood neuronal ceroid lipofuscinoses [PDF]
This original article is commented on by Mole on pages 156–157 of this issue. Abstract Aim To address disease progression in a cohort of patients with childhood‐onset neuronal ceroid lipofuscinosis (NCL), a group of genetic disorders leading to progressive dementia. Method In this retrospective study, selected clinical features (age at onset, at death,
Alessandro Simonati +29 more
wiley +2 more sources
Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients [PDF]
Background CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2) is an ultra-rare, neurodegenerative lysosomal storage disease, caused by an enzyme deficiency of tripeptidyl peptidase 1 (TPP1).
Sara E. Mole +20 more
doaj +6 more sources
A Novel Porcine Model of CLN2 Batten Disease That Recapitulates Patient Phenotypes
CLN2 Batten disease is a lysosomal disorder in which pathogenic variants in CLN2 lead to reduced activity in the enzyme tripeptidyl peptidase 1. The disease typically manifests around 2 to 4 years of age with developmental delay, ataxia, seizures, inability to speak and walk, and fatality between 6 and 12 years of age.
Jill M Weimer
exaly +3 more sources

